<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00231075</url>
  </required_header>
  <id_info>
    <org_study_id>FAG-2</org_study_id>
    <nct_id>NCT00231075</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV</brief_title>
  <official_title>National, Phase II Study Designed to Evaluate the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III and IV. FAG-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <brief_summary>
    <textblock>
      Safety and Efficacy of Paraplatin in combination with Taxol in patients of 70 years or older
      with epithelial ovary cancer F.I.G.O. stages III and IV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Main objective of this study is to evaluate the faisibility of chemotherapy with
      Paraplatin in combination with Taxol in patients of 70 years or older with epithelial ovary
      cancer F.I.G.O. stages III and IV and to determine principal predictive factors of this
      feasibility.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date>May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of the combination Paraplatine + Taxol (at least 6 cures have been administered for a given patient and for the treated population, 50% feasibility)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity assessment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <enrollment>75</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paraplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological proven diagnosis of epithelial ovary cancer F.I.G.O stages
             III or IV (when only cytological proven diagnosis is available: malignant cells and
             pelvis tumoral mass and increased CA-125 must be diagnosed simultaneously)

          -  Patient aged &gt; 70 years

          -  Neutrophil polynuclears &gt; 1500/mm3 and Platelets &gt; 100 000/mm3

          -  No clinical icterus

          -  Life expectancy of at least 3 months

        Exclusion Criteria:

          -  Previous diagnosis of malignancy

          -  Previous chemotherapy treatment

          -  Previous radiotherapy

          -  Hypersensitivity to products containing Cremophore EL

          -  Hepatic values: bilirubine &gt; 2*LSN, SGOT-SGPT &gt; 2*LSN and/or Alkalin phosphatase &gt;
             3*LSN

          -  Myocardiopathy with arrhythmia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Freyer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Lyon-Sud 69495 Pierre-Bénite cedex</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hosptalier Emile Roux</name>
      <address>
        <city>Eaubonne</city>
        <zip>95600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2005</study_first_submitted>
  <study_first_submitted_qc>September 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <last_update_submitted>November 2, 2005</last_update_submitted>
  <last_update_submitted_qc>November 2, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2005</last_update_posted>
  <keyword>Epithelial ovary cancer F.I.G.O. stages III or IV</keyword>
  <keyword>70 years or older</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

